High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL). This was a prospective phase II trial of rituximab plus fractionated cyclopho...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 23; no. 28; p. 7013
Main Authors:	Romaguera, Jorge E, Fayad, Luis, Rodriguez, Maria A, Broglio, Kristine R, Hagemeister, Frederick B, Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Sarris, Andreas H, Dang, Nam H, Wang, Michael, Beasley, Virginia, Medeiros, L Jeffrey, Katz, Ruth L, Gagneja, Harish, Samuels, Barry I, Smith, Terry L, Cabanillas, Fernando F
Format:	Journal Article
Language:	English
Published:	United States 01.10.2005
Subjects:	Administration, Oral Adult Age Factors Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cyclophosphamide - administration & dosage Dexamethasone - administration & dosage Disease-Free Survival Doxorubicin - administration & dosage Drug Administration Schedule Female Humans Infusions, Intravenous Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - pathology Male Middle Aged Rituximab Treatment Outcome Vincristine - administration & dosage
ISSN:	0732-183X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!